Primitive hematopoietic progenitor cells such as severe combined immunodeficiency-repopulating cells and long-term culture-initiating cells are enriched in CD34 þ CD38 À cells derived from various stem cell sources. In this study, to elucidate the features of such primitive cells at the molecular level, we tried to isolate genes that were preferentially expressed in umbilical cord blood (CB)-derived CD34 þ CD38
Introduction
Hematopoietic progenitor cells are a group of immature blood cells capable of differentiating into mature blood cells found in the peripheral blood. Most human hematopoietic progenitor cells are known to be enriched in the CD34 þ fraction derived from various stem cell sources, including umbilical cord blood (CB) and adult bone marrow (BM). 1, 2 However, these CD34 þ cells are a heterogeneous mixture of cells that can be further separated into the primitive CD38 À cells and the more mature CD38 þ cells. [3] [4] [5] [6] CD34 þ CD38 þ cells are already committed to differentiation and contain most of the lineage-committed colony-forming cells (CFCs). CD34 þ CD38 À cells are quiescent in terms of cell-cycling status and contain most of the severe combined immunodeficiency (SCID)-repopulating cells (SRCs) and long-term culture-initiating cells (LTC-ICs). 7, 8 To characterize such primitive hematopoietic cells at the molecular level, several approaches have been used. Graf þ CD38 þ cells and identified four mRNAs which were expressed at higher levels in CD34 þ CD38 À cells. One of these cDNAs (C40) encodes a known member of the subfamily of protein phosphatases (CL100). A second cDNA (C23) is identical to LR11 (gp250), a member of the low-density lipoprotein receptor family. The other isolates (C21 and C12) do not correspond to known protein sequences, but are homologous to EST sequences from a fetal brain library. Of them, C21 encodes a previously unknown gene that is a member of the WD-repeat protein family.
It has been demonstrated that CB contains a higher proportion of primitive hematopoietic cells, including SRCs and LTC-ICs, than BM. 7, 11, 12 Therefore, for the purpose of isolating the genes which function in such primitive cells, CB-derived CD34 þ CD38 À cells are considered to be more suitable materials than BM-derived CD34 þ CD38 À cells. Vasoactive intestinal peptide is a neuropeptide that elicits a broad spectrum of biological functions, including actions on natural and acquired immunity. [13] [14] [15] Although vasoactive intestinal peptide (VIP) affects a variety of immune functions, its primary, immunomodulatory function is anti-inflammatory in nature. VIP has been shown to inhibit cytokine production and proliferation of T cells and to inhibit several macrophage functions, including phagocytosis and chemotaxis, as well as LPS-induced cytokine and chemokine production. [16] [17] [18] [19] [20] The cloned receptors for VIP (VPAC1, VPAC2, and PAC1) are present in different subsets of immune cells. 14 Recently, it was reported that CD34 þ BM cells express VPAC1 receptor and that VIP has inhibitory effects on colony formation of CD34 þ BM cells. 21 In the present study, we tried to isolate the genes which were preferentially expressed in CD34 þ CD38 À CB cells using subtractive hybridization. The gene for VPAC1 receptor, a receptor for the neuropeptide VIP, was thereby isolated as a gene that was preferentially expressed in CD34 þ CD38 À CB cells, and it was shown to be expressed in not only CD34 þ CD38 À CB cells but also CD34 þ CD38 þ CB cells. We also assessed the effects of VIP on the proliferation of CBderived hematopoietic progenitor cells using in vitro cultures of CD34 þ CB cells and found enhanced proliferation of CD34 þ CB cells in response to stimulation with VIP. This suggested a possible mechanism for the involvement of VPAC1 receptor in the proliferation of CB-derived hematopoietic progenitor cells.
Materials and methods

Recombinant factor
Purified bacterially derived recombinant human (rh) interleukin-3 (IL-3), granulocyte macrophage-colony-stimulating factor (GM-CSF), granulocyte-colony-stimulating factor (G-CSF), stem cell factor (SCF), erythropoietin (Epo), and thrombopoietin (TPO) were generously supplied by Kirin Brewery (Tokyo, Japan). Recombinant human FLT3 ligand (FL) was generously supplied by Immunex Corporation (Seattle, WA, USA).
Cell preparations of Lin
Both CB and adult BM samples were obtained with informed consent. CB was obtained after normal vaginal deliveries at full term or deliveries by caesarian section. Nucleated cells were separated by hydroxyethyl starch sedimentation and cryopreserved until use. 22 The filter-retained fractions of BM grafts in allogeneic transplants containing enriched hematopoietic progenitor cells and differentiated postmitotic cells were recovered, and mononucleated cells were isolated therefrom by FicollHypaque (Amersham Pharmacia Biotech, Piscataway, NJ, USA) density gradient centrifugation and cryopreserved until use. 23 After rapid thawing, the Lin À CD34 þ cell-enriched fraction (À40% CD34 þ cells) was isolated from CB and BM cells using a StemSept column (StemCell Technologies, Vancouver, BC, Canada) and incubated at 371C overnight in RPMI 1640 containing 10% fetal calf serum. Then these cells were double-stained with anti-CD34-FITC (clone HPCA-2; BectonDickinson, San Jose, CA, USA) and anti-CD38-PE (clone HB7; Becton-Dickinson) or with anti-CD34-PE (clone HPCA-2; Becton-Dickinson) and anti-CD33-FITC (clone MY9; Beckman Coulter, Hialeah, FL, USA) antibodies. After washing, CBderived CD34 þ CD38 À and CD34 þ CD38 þ cells, and BMderived CD34 þ CD33 þ cells were sorted using an Epics Elite cell sorter (Beckman Coulter). Sorting gates are shown in Figure 1 . The phenotypic purity of the sorted populations consistently exceeded 95%.
Construction of poly (
Poly (A) PCR was performed according to the protocol described by Brady et al. 24 with some modifications. Total nucleic acids were extracted from sorted fractions (containing 5000-6000 cells) according to the Mini-GT protocol, redissolved in 8 ml of lysis buffer containing 56 mM Tris-HCl, pH 8.3, 83 mM KCl, 3.3 mM MgCl 2 , 0.5% NP-40, 275 U/ml Prime RNase Inhibitor (Eppendorf, Hamburg, Germany), and 275 U/ml RNA guard (Amersham Pharmacia Biotech), treated with 1 U of DNase I Amplification Grade (Gibco-BRL Lifetechnologies, Rockville, MD) at 371C for 30 min, and heat-inactivated (951C for 5 min). The resultant RNA solution was mixed with 1 ml of cDNA primer mix containing 0.2 mM (dT) 24 primer, 0.1 mM dNTP, 1.2 U of Prime RNase inhibitor, and 1.2 U of RNA guard, heated to 651C for 3 min, quenched on ice, reverse-transcribed with 100 U of Moloney-murine leukemia virus (M-MLV) reverse transcriptase (Gibco-BRL Lifetechnologies) and 1.3 U of avian myeloblastosis virus (AMV) reverse transcriptase (Promega, Madison,WI, USA) at 371C for 30 min, and heat inactivated (651C for 10 min). Then, the resultant cDNA solution was mixed with 11 ml of 2 Â tailing buffer containing 0.2 M potassium cacodylate (pH 7.2), 4 mM CoCl 2 , 0.4 mM dithiothreitol (DTT), 3.0 mM dATP, and 10 U of terminal transferase (Boeringer Manheim, Manheim, Germany), incubated at 371C for 15 min, and heated to 651C for 10 min. Aliquots (10 ml) of the above cDNA solutions were subjected to PCR in a 50-ml reaction solution containing a 3 0 -(dT) 24 -containing 60-base primer (KV-(dT) 24 primer: 5 0 -GGTAACTAATAC-GACTCACTATAGGGAGATGAATTC-(dT) 24 -3 0 ) as described by Brady et al. 24, 25 First-round PCR was performed for 25 cycles (941C for 1 min, 501C for 2 min, 721C for 6 min). After the firstround PCR, 1 ml of the first PCR product was added to 49 ml of the same PCR solution described above, and the second-round PCR was performed for 30 cycles (941C for 1 min, 501C for 1 min, 721C for 2 min).
Subtractive hybridization
Subtractive hybridization to enrich cDNAs present in CD34 þ CD38 À CB cells but not in CD34 þ CD33 þ BM cells was performed according to the protocol described by Brady et al, with some modifications. 25, 26 Tester cDNA derived from CD34 þ CD38 À CB cells was amplified by poly (A) PCR using KV-(dT) 24 primer. The PCR product was electrophoresed on 1% low melting temperature agarose and cDNA of more than 300 bp was recovered. Biotinylated driver cDNA derived from CD34 þ CD33 þ BM cells was generated as follows. cDNA was amplified by poly (A) PCR using 5 0 -biotinylated LV-(dT) 24 primer (5 0 -CCTAAGTAATAGCAGTGAGTATACCCACATGAATTC-(dT) 24 -3 0 ). This poly (A) PCR product was digested with EcoRI for 4 h to remove the LV sequence. 5 0 -Biotinylated LV-(dT) 24 primer and undigested cDNA containing the LV sequence were removed using Vectrex Avidin D (Vector Laboratories, Burlingame, CA, USA). Then, the resultant cDNA not having the LV sequence was photobiotinylated with Photoprobebiotin (Vector Laboratories) according to the manufacturer's protocol and used Immunophenotype of CD34 þ -enriched CB and BM cells from lymphoid cell region based on forward and side scatter.
Growth-promoting effects of VIP on CD34 þ CB cells M Kawakami et al as a driver. Hybridization between 4 mg of biotinylated driver cDNA and 100 ng of tester cDNA was performed as described by Brady et al. 25 Unhybridized tester cDNA was recovered using Vectrex avidin D and reamplified by PCR primed with KV 30 primer (5 0 -GGTAACTAATACGACTCACTATAGGGAGAT-3 0 ) for 35 cycles (941C for 1 min, 551C for 1 min, 721C for 2 min). The resultant amplified difference cDNA was electrophoresed on 1% low melting temperature agarose and cDNA of more than 300 bp was recovered and subjected to an additional three rounds of subtractive hybridization against 4 mg of driver cDNA. The first, second, and third rounds of subtractive hybridization were performed using 10 ng, 100 pg, and 100 pg of tester cDNA, respectively.
Library screening
For library cloning, amplified differentially expressed cDNA was cleaved within the KV sequence with EcoRI, purified, and ligated into EcoRI-digested, dephosphorylated lambda ZAP II phage vector (Stratagene, La Jolla, CA, USA) to construct a phage library according to the manufacturer's protocol. The phage library was plated, and each clone was excised in vivo to release the pBluescript phagemid. The plasmid DNA of each clone was extracted and used as a template DNA for sequencing reactions, and the insert sequence of the plasmid DNA was amplified by PCR using T3 and T7 primers and used as the cDNA probe for Southern hybridization.
Southern hybridization with poly (A) PCR-based cDNA libraries
In all, 4 ml of poly (A) PCR products amplified with KV-(dT) 24 primer derived from CD34 þ CD38 À and CD34 þ CD38 þ CB cells and CD34 þ CD33 þ BM cells were electrophoresed on 1.2% agarose gels and transferred onto nylon membranes (Hybond N þ , Amersham Pharmacia Biotech). The membranes were hybridized with [ 
RT-PCR
Total RNA was isolated from sorted CB-derived CD34 þ CD38
À and CD34 þ CD38 þ cells (each of the sorted fractions contained 10 000-20 000 cells) using Trizol reagent (Life Technologies, Grand Island, NY, USA) and reverse-transcribed with ReverTraAce reverse transcriptase (Toyobo Biochemicals, Osaka, Japan) using random octamer primer (Toyobo Biochemicals) in a final volume of 20 ml. A volume of 1 ml of the reverse transcription reaction mixture was subsequently used as template for RT-PCR and real-time RT-PCR. In all, 40 cycles of RT-PCR were performed for VPAC2 receptor (accession: X95097) and PAC1 receptor (accession: D17516), as described previously. 27 
Real-time RT-PCR of VPAC1 receptor
The expression levels of VPAC1 receptor (accession: L13288) were quantitated using TaqMan real-time RT-PCR according to the manufacturer's instructions (Applied Biosystems). The sequences of specific primers and probes conjugated with 5 0 -reporter dye 6-carboxytetramethylrhodamine (6-FAM) are shown in the appendix. b-actin (accession: X00351) was used as an internal control. In all, 45 cycles of PCR were performed in triplicate tubes. The annealing/extension steps were done at 621C. Serial dilutions of cloned VPAC1 receptor and b-actin cDNAs were used to construct standard curves of copy number vs threshold cycle (Ct). The standard curves were constructed with six serial 1/10 dilutions (10 2 -10 7 copies for VPAC1 receptor and 10 3 -10 8 copies for b-actin). To normalize for differences in RNA loading for RT-PCR, the ratio of the copy number of VPAC1 receptor to the copy number of b-actin was taken as the expression level in the samples.
Clones
A 118-bp human VPAC 1 receptor cDNA fragment was amplified from the human B-cell lymphoma cell line Daudi by RT-PCR with the sense and antisense primers used in the TaqMan real-time RT-PCR described above. The 118-bp RT-PCR product was cloned into TA vector (Invitrogen, Carlsbad, CA, USA). A 101-bp human b-actin cDNA fragment was amplified from human peripheral blood by RT-PCR with the sense and antisense primers used in the TaqMan real-time RT-PCR described above. The 101-bp RT-PCR product was cloned into TA vector (Invitrogen).
Serum-free single-cell liquid culture
Clone sorting of Lin À CD34 þ CB and BM cells was performed using a FACSVantage (Beckton Dickinson) with an automated cell deposition unit (CloneCyt, Beckton Dickinson) as previously reported. 28 Serum-free liquid suspension culture was performed in 96-well microtiter plates. Cultures consisted of single Lin À CD34 þ CB and BM cells in wells containing X-VIVO 20 (Biowhittaker, Walkersville, MD, USA) supplemented with three cytokines: 20 ng/ml rh FL, 20 ng/ml rh SCF, and 100 ng/ml rh TPO and the indicated concentrations of VIP (120 cells for each VIP concentration). Cells were incubated for up to 7 days at 371C in a fully humidified atmosphere flushed with a combination of 5% CO 2 , 5% O 2 , and 90% N 2 . Each well was scanned under an inverted microscope on days 4 and 7 of incubation. The number of cells was directly counted in situ when a positive well (^4 cells per well) was identified.
Serum-free clonal culture
Colony formation by 200 CB-and BM-derived Lin À CD34 þ cells was assessed in 35-mm Lux suspension culture dishes (No. 171099, Nunc Inc., Naperville, IL, USA) and was performed in serum-free methylcellulose medium containing five colonystimulating factors (five CSFs) in the absence or the presence of VIP exactly as reported previously. 28 The final concentrations of each factor were as follows: rh SCF 20 ng/ml; rh IL-3 10 ng/ml; rh GM-CSF 10 ng/ml; rh G-CSF 20 ng/ml; rh Epo 2 U/ml; VIP 10 À9 M. In part of the experiments, ASF 104 medium containing these concentrations of five CSFs was additionally overlaid on the VIP-containing or VIP-free clonal cultures on days 3 or 5 of incubation in order to evaluate the direct effect of VIP on the survival of hematopoietic progenitor cells. Dishes were incubated at 371C in a fully humidified atomosphere flushed with a combination of 5% CO 2 , 5% O 2 , and 90% N 2 . On days 12-14 of incubation, all colonies were counted under an inverted microscope.
Growth-promoting effects of VIP on CD34 þ CB cells M Kawakami et al Dexter-type long-term culture BM stromal layers were established from the filter-retained fraction of BM grafts as previously described. 29 Briefly, freshly isolated filter-retained BM cells were suspended at the concentration of 2 Â 10 5 cells/ml in Myelocultt medium (StemCell Technologies) supplemented with 10 À6 M hydrocortisone sodium succinate, and were then cultured at 371C in 5% CO 2 in 175-cm 2 flasks (Falcon 353028, Becton Dickinson). At approximately 1-2 weeks, when the adherent cells reached confluence, nonadherent cells were removed and adherent cells were trypsinized, recovered, resuspended in the same medium, and seeded in 24-well plates (No. 143982, Nunc Inc.). After the cells reached confluence, the plates were subjected to g-irradiation of 15 Gy delivered with a cesium source and cultured at 331C in 5% CO 2 . VIP at each concentration (0, 10 À11 , and 10 À9 M) was added to wells containing 0.8 ml of medium, and the next day 300-1000 CD34 þ CB cells were deposited per well. Half of the medium containing each concentration of VIP was replaced every 5 days. At week 5 of culture, adherent cells were trypsinized and recovered, and CFCs were enumerated using serum-containing clonal culture medium supplemented with the five CSFs as previously described. 28 
Statistical analysis
The significance of differences in mean values was determined using Student's t-test. In single-cell suspension cultures, the significance of differences in cell number per clone and well number containing a specified number of cells was determined using Scheffé's F-test and the w 2 -test, respectively.
Results
Construction of subtracted library
To characterize the primitive hematopoietic progenitor cells at the molecular level, we tried to isolate the genes that were preferentially expressed in CD34 þ CD38 À CB cells. To this end, we constructed a cDNA library of CD34 þ CD38 À CB cells using poly (A)-PCR and removed 'housekeeping gene' products from it using subtractive hybridization. To accomplish this strategy, the nucleotide sequences present in CD34 þ CD33 þ BM cells, which are considered to be mature cells depleted of primitive cells such as LTC-ICs, were subtracted from CD34 þ CD38 À CBderived cDNA. 30, 31 The efficiency of the subtraction was checked by the reduction in the amount of b-actin cDNA, which was reduced approximately 10-fold as a result of four rounds of subtraction.
The subtracted cDNA of CD34 þ CD38 À CB cells was cloned into lambda ZAP II to produce a phage library. The library was plated, and individual plaques were picked up. In all, 43 insertcontaining clones were sequenced (Table 1) . By homology search, one clone was seen four times, three clones three times, two clones twice, and the remaining 26 clones once. Thus, 32 clones were identified as individually different clones. Of these clones, 18 were homologous to cDNA clones (eight clones, known genes; 10 clones, unknown genes) and the remaining 14 were not homologous to any of the cDNA clones examined.
Southern hybridization with poly (A) PCR-based cDNAs
To check whether the subtraction worked well, that is, whether each subtracted clone was more highly expressed in Table 1 Characteristics of isolated clones As a result of homology search, 32 different clones were isolated from 43 subtracted cDNA clones derived from CD34 + CD38 À CB cells. Each clone was Southern-hybridized with poly (A)-PCR-based cDNAs derived from the indicated CB-and BM-cell-fractions to determine the expression levels in them. *The intensity was -+++: very strong compared to that of the b-actin gene, ++: between +++ and +, +: clear but not strong, 7: very weak or À: not detectable. þ CD38 À CB and CD34 þ CD38 þ CB cells. In all, 22 clones were not expressed in any cell population or were expressed at very low levels. The remaining seven clones were highly expressed in all the three cell populations. Among these clones, the clone for VPAC1 receptor (clone C52), a receptor for the neuropeptide VIP that was preferentially expressed in CD34 þ CD38 À CB cells, was selected for further detailed examination, since some neuropeptides, including VIP, have been reported to function in immune and hematopoietic systems.
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Expression level of C52 (VPAC1 receptor)
Clone C52 contained a 196-bp DNA fragment, and its sequence was identical to the 3 0 end (nucleotides 2559-2754) of the vasoactive intestinal peptide 1 receptor (VIP1/VPAC1 receptor, accession: L13288). To quantify the expression level of this gene, the sequence between nucleotides 468 and 585 was amplified and quantified by real-time RT-PCR (the expression levels were expressed as the ratio of the copy number of VPAC1 receptor genes to the copy number of b-actin genes Â 10 5 ). The mean expression levels in three independent experiments are shown in Figure 2 . The VPAC1 receptor gene was expressed in not only CD34 
Expression of other VIP receptors in CD34 þ CB cells
Since both the VPAC2 receptor and PAC1 receptor genes belong to the same gene family as the VPAC1 receptor gene, the expression of these two genes was examined by RT-PCR. However, their expression was undetectable in CD34 þ CB cells (data not shown).
Effects of VIP on proliferation of single CD34
þ CB cells in serum-free suspension culture It has been reported that VIP has inhibitory effects on the colony formation of BM-derived CD34 þ cells. 21 Therefore, we investigated whether VIP inhibits the proliferation of CD34 þ CB cells induced by three early-acting cytokines: FL, SCF, and TPO, using serum-free single-cell suspension cultures. Single CD34 þ CB cells were deposited in wells (120 single cells for each concentration of VIP) and the pattern of proliferation was observed on days 4 and 7 using an inverted microscope. Wells containing four or more cells were scored as positive clones and the number of cells per clone was counted and is shown in Figure 3 ((a) on day 4 and (b) on day 7, respectively), and the data are summarized in Table 2 . Unexpectedly, growthpromoting effects were observed. That is, on day 4, the number of positive clones was significantly increased in cultures with 10 À9 and 10 À7 M VIP compared to the number in cultures with medium alone (Po0.05; Table 2 ). The cell number per clone was not changed significantly by the addition of VIP compared to the number in cultures with medium alone. However, the number of clones containing 16 or more cells was significantly increased in cultures with 10 À9 M VIP compared to the number in cultures with medium alone or 10 À11 M VIP (Po0.01; Table 2 and closed circles in Figure 3a) . In most of these clones, the cell number per clone continued to increase until day 7 (closed circles in Figure 3b ). On day 7, the cell number per clone was significantly increased in cultures with 10 À9 M VIP compared to that in cultures with medium alone (Po0.01), or with 10 À13 or 10 À11 M VIP (Po0.05) and was increased in cultures with 10 À7 M VIP compared to that in cultures with medium alone (Po0.01) or with 10 À11 VIP (Po0.05) (Figure 3b) . Furthermore, the number of clones containing 31 or more cells was significantly increased in cultures with 10 À9 and 10 À7 M VIP compared to that in cultures with medium alone or 10 À11 or 10 À13 M VIP (Table 2 ). These results demonstrate that the growth-promoting effects of VIP on CD34 þ CB cells were maximal at the concentration of 10 À9 M. Accordingly, we also cultured single CD34 
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þ CB cells M Kawakami et al day 7 were all slightly increased by the addition of VIP; however, these increases were not significant ( Table 2 ). The cell number per clone was not increased significantly by the addition of VIP on either day 4 or day 7 ( Figure 3 ).
Synergistic effects of VIP and the five CSFs on colony formation of CD34
þ CB cells Figure 4 . CFU-GM, CFU-Mix, and total CFCs were significantly increased over the corresponding levels in cultures without VIP by the addition of 10 À9 M VIP (Po0.05), indicating that VIP enhances the proliferation of committed progenitor cells in synergy with the early-acting cytokines. We also performed clonogenic assays of CD34 þ BM cells under the same conditions. However, the number of CFCs was not changed by the addition of VIP (data not shown).
Effects of VIP alone on CB-derived CFCs
The above findings indicate that VIP promotes the proliferation of CB-derived CD34 þ cells and enhances their colony formation in synergy with early-acting cytokines. To investigate whether VIP exerts effects on CB-derived colony-forming cells on its own or not, we performed serum-free clonogenic assays of CD34 þ CB cells with delayed addition of the five CSFs. In total, 200 CD34
þ CB cells were cultured from day 0 in serum-free methylcellulose medium in the absence or presence of 10 À9 M VIP, and liquid medium containing the five CSFs was added on days 3 or 5 or not added. On day 14, the number of total colonies was counted. Representative data from two independent experiments are shown in Figure 5 . Without the addition of the five CSFs, there were no detectable colonies in the cultures with VIP or in those with medium alone. In cultures with addition of the five CSFs on days 3 and 5, the numbers of total CFCs were significantly higher in the presence of VIP than in the absence of VIP (81.373.1 vs 71.771.5 in cultures with day 3 addition, Po0.01; 37.773.5 vs 24.072.6 in cultures with day 5 addition, Po0.01, respectively).
Effects of VIP on CB-derived CFCs in Dexter-type long-term cultures
The above results demonstrating that VPAC1 receptor was preferentially expressed in CD34 þ CD38 À CB cells suggested an important role of VIP in CB-derived primitive hematopoietic progenitor cells, including LTC-ICs. We therefore investigated the effects of VIP on such primitive cells derived from CB, using Dexter-type long-term cultures. CD34
þ CB cells were cultured on irradiated allogeneic stromal cell layers in the absence or presence of VIP (10 À11 and 10 À9 M). CFCs in the adherent cells were enumerated at week 5. Representative data from three independent experiments are shown in Figure 6 . The number of CFCs at week 5 was increased by 1.5-and 2.1-fold over the number in cultures with medium alone by the addition of 10 À11 and 10 À9 M (Po0.05) VIP, respectively. These results clearly indicate that VIP supports the proliferation or survival of primitive hematopoietic progenitor cells.
Discussion
In this study, to characterize primitive hematopoietic progenitor cells such as LTC-ICs and SRCs at the molecular level, we tried to isolate genes which were preferentially expressed in CD34 þ CD38 À CB cells. To this end, we constructed a cDNA library derived from CD34 þ CD38 À CB cells using poly (A)-PCR 
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þ CB cells M Kawakami et al and performed subtractive hybridization to remove 'housekeeping gene' products from it and to enrich the genes which function in the primitive hematopoietic cells. [24] [25] [26] 
CD34
þ CD38 þ cells derived from various stem cell sources, including CB and BM, which were used as the source of driver cDNA for subtraction in the previous report, also contain a substantial number of primitive hematopoietic progenitor cells such as LTC-ICs. 10 Therefore, when CD34 þ CD38 þ CB cells are used for constructing driver cDNA, the genes which function in such primitive cells may also be subtracted. Among CB-and BM-derived CD34 þ CD38 þ cells, which can be separated into þ CD33 þ BM cell fraction as a source of driver cDNA for the subtraction.
It was reported recently that VPAC1 receptor, one of the receptors for the neuropeptide VIP, is expressed in BM-derived CD34 þ cells. 21 It has not, however, been determined whether CD34 þ CD38 À cells, which are well known to contain primitive hematopoietic progenitors, express VPAC1 receptor or not. In this report, we demonstrated for the first time that VPAC1 receptor is expressed in CD34 þ CD38 À cells as well as in CD34 þ CD38 þ cells derived from CB ( Figure 2 ). This finding suggests that VIP acts on both primitive CD34 þ CD38 À cells and more mature CD34
þ CD38 þ cells of CB. Growth-promoting effects of VIP on CD34 þ CB cells M Kawakami et al
We investigated the direct effects of VIP on the proliferation of CD34 þ CB cells using serum-free single-cell suspension cultures in the presence of three early-acting cytokines: FL, SCF, and TPO. 32 The addition of VIP significantly increased the clonal growth of CB-derived CD34 þ cells. This growthpromoting effect was observed as early as day 4 of incubation and continued until day 7 ( Figure 3) . These results clearly demonstrate that VIP acts directly on CD34
þ CB cells and that signaling through VPAC1 receptor promotes the proliferation of these cells from a very early phase in the presence of simultaneous stimulation by FL, SCF, and TPO. In contrast to CD34 þ CB cells, the growth-promoting effects of VIP on single CD34 þ BM cells in cultures under the same conditions were weak and not evident by statistical analysis.
Using serum-free clonogenic assays, we also demonstrated that VIP (10 À9 M) significantly enhanced the formation of various types of colonies from CD34 þ CB cells supported by five CSFs but not from CD34 þ BM cells (Figure 4) . Together with the findings obtained from serum-free single-cell suspension cultures, this strongly suggests that VIP acts directly on VPAC1 receptor-expressing committed progenitor cells derived from CB and promotes their colony formation in synergy with earlyacting cytokines, and that the growth-promoting effects of VIP on BM-derived hematopoietic progenitor cells are weaker than those on CB-derived hematopoietic progenitor cells.
There have been two previous reports about the direct effects of VIP on hematopoietic progenitor cells. Broome et al 33 showed that VIP did not affect the colony formation of CFU-GM from adult mouse enriched CFU-GM cell preparations in a serum-containing clonogenic assay in medium supplemented with IL-3. Rameshwar et al 21 showed that VIP inhibited colony formation of CFU-GM and BFU-E from human purified CD34 þ BM cells in a serum-containing clonogenic assay in medium supplemented with IL-3 for CFU-GM or with GM-CSF and Epo for BFU-E. Therefore, whether or not VIP directly affects BMderived hematopoietic progenitor cells has remained controversial. It has been well documented that hematopoietic cytokines show more potent synergistic effects on the proliferation of human hematopoietic progenitor cells under serum-deprived conditions than under serum-containing conditions. [34] [35] [36] This finding suggests a possible inhibitory effect of serum on the proliferation of hematopoietic progenitor cells. We therefore performed human progenitor cell assays under serum-free conditions in order to precisely elucidate the hematopoietic effects of soluble factors, including VIP, on CD34 þ CB and BM cells, and demonstrated that VIP enhanced colony formation of CD34 þ CB cells but not of CD34 þ BM cells in synergy with the five CSFs. Our results definitely documented that VIP promoted the proliferation of CB-derived committed progenitor cells in synergy with the five CSFs, and that the responses to VIP of BMderived progenitor cells were weaker than those of CB-derived ones.
To investigate whether VIP on its own supports the proliferation and survival of CB-derived hematopoietic progenitor cells, we performed serum-free clonogenic assays of CD34 þ CB cells with delayed addition of the five CSFs. Without the five CSFs, no colonies were formed in the presence or the absence of VIP ( Figure 5 ). This implies that VIP alone could not induce the proliferation of CB-derived hematopoietic progenitors to form colonies. However, with delayed addition of the five CSFs on days 3 or 5 of culture, the number of total colonies was significantly higher in cultures with VIP than in cultures with medium alone ( Figure 5 ). This suggests that VIP on its own supports the survival of CB-derived hematopoietic progenitor cells under cytokine-free conditions.
To investigate the effects of VIP on CB-derived LTC-ICs, which are immature cells possessing colony-forming capacity even after 5 weeks of culture on stromal layers, we performed Dexter-type long-term cultures using allogeneic stromal cells in the presence or absence of VIP. We thereby demonstrated for the first time that the addition of VIP increased CFCs at week 5 of long-term cultures ( Figure 6 ). Two possible mechanisms of this increase should be considered. One mechanism is through direct growth-promoting effects of VIP on LTC-ICs. Our finding that VPAC1 receptor is highly expressed in CD34 þ CD38 À CB cells together with the fact that LTC-ICs are enriched in CD34 þ CD38 À cells suggest that VPAC1 receptor is highly expressed in CB-derived LTC-ICs. Taken with our finding that VIP exerts direct growth-promoting effects on CD34 þ CB cells, this supports the notion of the direct growth-promoting effects of VIP on VPAC1 receptor-expressing LTC-ICs. Another possible mechanism is through the effects of VIP on BM stromal cells. Rameshwar et al 21 showed that VIP induced TNF-a and TGF-b production in VPAC1 receptor-expressing BM stromal cells, and that these two factors contributed to inhibitory effects on colony formation in clonogenic assays of whole BMNCs. Although the cellular source of TNF-a and TGF-b in BM stromal cells is not known, macrophages represent one possible source. According to previous reports, VIP inhibited TNF-a and TGF-b production in murine LPS-stimulated macrophages without inducing TNF-a and TGF-b release from unstimulated macrophages. 16, 17 These results are contradictory to the findings of Rameshwar et al cited above. Cai et al 18 showed that VIP increased IL-6 production by rat BM-derived stromal cells. Martinez et al 19 showed that VIP inhibited IL-6 production by LPS-stimulated murine macrophages, but induced IL-6 production by unstimulated macrophages and by macrophages stimulated with very low LPS concentrations. Taken together, these findings suggest that VIP might induce or inhibit the production of certain cytokines depending on the conditions of the BM microenvironment. We should search for factors whose production by BM stromal cells is induced or inhibited by VIP, and should investigate how they affect primitive hematopoietic progenitor cells. Growth-promoting effects of VIP on CD34 þ CB cells M Kawakami et al
The growth-promoting effects of VIP shown in this study were more obvious at the concentration of 10 À9 M compared to 10 À11 M, which is the physiological concentration in peripheral blood. 37, 38 Since neuropeptides, including VIP, are rapidly degraded in the circulation, it is thought that VIP acts very locally and that VIP-producing cells exist in the vicinity of the target cells. Neuropeptide-containing nerve fibers project into BM and terminate in association with stromal cells and within the parenchyma. 39, 40 Moreover, neuropeptides, including VIP, are secreted by nerve ends in the BM microenvironment. It has been suggested that nerve fibers contribute to the regulation of blood cell production, although there is some controversy about these findings. [41] [42] [43] [44] Based on these findings taken together, it can be speculated that the growth-promoting effect of VIP on hematopoietic progenitor cells is exerted predominantly in the vicinity of VIP-producing nerve terminals in the BM microenvironment. How the growth-promoting effects of VIP contribute to the in vivo regulation of hematopoiesis remains unknown and should be investigated in future studies. Recently, several other neuropeptides, such as substance P, somatostatin, and calcitonin-gene related peptide, have been reported to have effects on hematopoietic progenitor cells. [45] [46] [47] [48] How VIP regulates hematopoiesis in concert with these neuropeptides should be investigated in the future. Growth-promoting effects of VIP on CD34 þ CB cells M Kawakami et al
